
Opinion|Videos|December 5, 2025
Introductions
Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.
Advertisement
Episodes in this series
In this opening segment, the panelists introduce themselves and set the stage for the series, outlining the purpose of the discussion and the key CDK4/6 inhibitor data featured at ESMO 2025. Viewers are oriented to the trials that will anchor the conversation and the clinical questions the experts aim to explore throughout the program.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5

























